In December 2024, the Shanghai-based biotech caught the eye of Candid Therapeutics, with the two inking a research deal for novel T-cell engager candidates for various autoimmune indications.

The changes will extend the biotech’s cash runway into 2027, compared to late 2026 under the previous plan. Rocket’s PKP2 and BAG3 programs are on track and unaffected by the clinical hold ...

Biotechnology companies have been a cornerstone of the pharmaceutical industry since the mid-1990s. Today, many of these firms have matured into profitable companies. We divide biotechs into three ...

(Reuters) -Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter ...

Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation’s pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for ...

After reaching an important support level, IO Biotech, Inc. (IOBT) could be a good stock pick from a technical perspective. IOBT recently experienced a "golden cross" event, which saw its 50-day ...

Fortress Biotech, Inc. has announced the acquisition of its subsidiary Checkpoint Therapeutics, Inc. by Sun Pharmaceutical Industries Limited, which closed on May 30, 2025, after receiving ...

Biotech firm touts new AI lung disease drug discovery amid third Hong Kong IPO attempt. Insilico Medicine said results of a clinical trial in China showed positive results in treating idiopathic ...

Today's biotech news includes KJ's homecoming after groundbreaking CRISPR therapy, Vinay Prasad on rare diseases, and more. Skip to Main Content Manage alerts for this article ...

Pharmalittle: We’re reading about a biotech IPO slump, FDA oversight of pharma ads, and more. Eli Lilly is wagering up to $1 billion on a private biotech that is developing non-opioid pain drugs .

With our incredible universities, educated workforce and geographic location, I firmly believe Connecticut can be the next superhub of biotech.

A biotechnology company based in Westchester, N.Y., Regeneron pledged to work with an independent, court-appointed customer-privacy ombudsman to protect clients — a requirement of all bidders in ...